Abstract:The treatment of complex and multifactorial diseases constitutes a big challenge in day-to-day clinical practice. As many parameters influence clinical phenotypes, accurate diagnosis and prompt therapeutic management is often difficult. Significant research and investment focuses on state-of-the-art genomic and metagenomic analyses in the burgeoning field of Precision (or Personalized) Medicine with genome-wide-association-studies (GWAS) helping in this direction by linking patient genotypes at specific polymorphic sites (single-nucleotide polymorphisms, SNPs) to the specific phenotype. The generation of polygenic risk scores (PRSs) is a relatively novel statistical method that associates the collective genotypes at many of a person's SNPs to a trait or disease. As GWAS sample sizes increase, PRSs may become a powerful tool for prevention, early diagnosis and treatment. However, the complexity and multidimensionality of genetic and environmental contributions to phenotypes continue to pose significant challenges for the clinical, broad-scale use of PRSs. To improve the value of PRS measures, we propose a novel pipeline which might better utilize GWAS results and improve the utility of PRS when applied to Alzheimer's Disease (AD), as a paradigm of multifactorial disease with existing large GWAS datasets that have not yet achieved significant clinical impact. We propose a refined approach for the construction of AD PRS improved by (1), taking into consideration the genetic loci where the SNPs are located, (2) evaluating the post-translational impact of SNPs on coding and non-coding regions by focusing on overlap with open chromatin data and SNPs that are expression quantitative trait loci (QTLs), and (3) scoring and annotating the severity of the associated clinical phenotype into the PRS. Open chromatin and eQTL data need to be carefully selected based on tissue/cell type of origin (e.g., brain, excitatory neurons). Applying such filters to traditional PRS on GWAS studies of complex diseases like AD, can produce a set of SNPs weighted according to our algorithm and a more useful PRS. Our proposed methodology may pave the way for new applications of genomic machine and deep learning pipelines to GWAS datasets in an effort to identify novel clinically useful genetic biomarkers for complex diseases like AD.

Identifying Genes Associated with Alzheimer's Disease Using Gene-Based Polygenic Risk Score

Identifying Shared Diagnostic Genes and Mechanisms in Vascular Dementia and Alzheimer's Disease Via Bioinformatics and Machine Learning

Identification of Novel Drug Targets for Alzheimer's Disease by Integrating Genetics and Proteomes from Brain and Blood.

Identification of novel drug targets for Alzheimer’s disease by integrating genetics and proteomes from brain and blood

Improving the Utility of Polygenic Risk Scores as a Biomarker for Alzheimer's Disease

Prediction of clinical diagnosis of Alzheimer’s disease, vascular, mixed, and all-cause dementia by a polygenic risk score and APOE status in a community-based cohort prospectively followed over 17 years

Validating Gwas-Identified Risk Loci for Alzheimer'S Disease in Han Chinese Populations

An Integrated Brain-Specific Network Identifies Genes Associated with Neuropathologic and Clinical Traits of Alzheimer's Disease.

Genome-wide epistasis analysis for Alzheimer’s disease and implications for genetic risk prediction

Association of Polygenic Risk Score with Age at Onset and Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease in a Chinese Cohort

Polygenic Risk Scoring is an Effective Approach to Predict Those Individuals Most Likely to Decline Cognitively Due to Alzheimer’s Disease

System-Level Analysis of Alzheimer's Disease Prioritizes Candidate Genes for Neurodegeneration

Alzheimer's disease heterogeneity explained by polygenic risk scores derived from brain transcriptomic profiles

Integrate GWAS, Eqtl, and Mqtl Data to Identify Alzheimer’s Disease-Related Genes

An integrated brain-specific network identifies genes associated with neuropathologic and clinical traits of Alzheimer’s disease

Deep Post-Gwas Analysis Identifies Potential Risk Genes and Risk Variants for Alzheimer’s Disease, Providing New Insights into Its Disease Mechanisms

Polygenic Risk Score Reveals Genetic Heterogeneity of Alzheimer’s Disease between the Chinese and European Populations

Computational Drug Repurposing for Alzheimer’s Disease Using Risk Genes From GWAS and Single-Cell RNA Sequencing Studies

Polygenic Risk Scores in Alzheimer’s Disease Genetics: Methodology, Applications, Inclusion, and Diversity

Genome-wide significant, replicated and functional risk variants for Alzheimer's disease.

Identification of Alzheimer's Disease-Related Genes Based on Data Integration Method